AaronThomasGerdsMDMS

Hematology • Cleveland, OH

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Medicine, Cleveland Clinic Learner College of Medicine of Case Western Reserve

Join to view full profile

Dr. Gerds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gerds' full profile

Already have an account?

Office
9500 Euclid Ave
CA-60
Cleveland, OH 44195
Phone+1 216-445-9840

Summary

Dr. Aaron Gerds completed his undergraduate degree with honors (B.A. in biology and chemistry) at Hope College in Holland, Michigan. He then obtained his M.D. from Loyola University Chicago Stritch School of Medicine. Dr. Gerds stayed at Loyola University Hospital for his Internal Medicine residency training where he also served as chief resident. This is when he first became interested in hematology while analyzing the results of clinical trials under the mentorship of Dr. Patrick Stiff. This experience led him to pursue a master’s degree in clinical research methods and epidemiology during residency. Dr. Gerds then went to Seattle where he completed his hematology/oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center. During his fellowship, he was awarded the ASBMT’s New Investigator Award. Under the mentorship of Drs. Joachim Deeg and Bart Scott, Dr. Gerds subspecialized in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as myelodsyplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with a special emphasis on allogeneic hematopoietic cell transplantation. Dr. Gerds is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving on the Test Materials Development Committee. As Assistant Professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute, Dr. Gerds serves as the principle investigator for a number of clinical trials for the treatment of MPNs, and is focused on developing novel therapies for these patients.

Dr. Aaron Gerds - Bio VIdeo

Dr. Aaron Gerds - Cleveland Clinic Taussig Cancer Institute.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2010 - 2013
Loyola University ChicagoMSc, Clinical Research Methods and Epidemiology, 2008 - 2011
Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2010
Loyola University Chicago Stritch School of MedicineClass of 2006
Hope CollegeB.A., Biology and Chemistry, Cum Laude, 1998 - 2002

Certifications & Licensure

OH State Medical License 2013 - 2027
WA State Medical License 2010 - 2014
IL State Medical License 2006 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

New Investigator Award American Society for Blood and Marrow Transplantation, 2013
Scholar, Clinical Research Training Course American Society for Blood and Marrow Transplantation, 2012
Alpha Omega Alpha Loyola University Stritch School of Medicine, 2010
Resident of the Year Loyola University Internal Medicine Residency,, 2008
Resident Teacher of the Year Loyola University Internal Medicine Residency,, 2008
Winner, Loyola Internal Medicine Clinical Vignette Competition 2006
Winner, National Medical Student Research Competition American College of Physicians, 2004
Sigma Xi Senior Research Award Hope College, 2002
Join now to see all

Clinical Trials

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
The National Myelodysplastic Syndromes (MDS) Study Start of enrollment: 2016 Jun 13
Recruiting
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2018 Jan 26
Completed
Phase 2
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis Start of enrollment: 2021 Feb 18
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia Start of enrollment: 2024 Apr 22
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

58 citations
Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome
Zhantao Yang, Sioban Keel, Akiko Shimamura, Li Liu, Aaron T. Gerds
Science Translational Medicine. 2016-05-11
9 citations
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Brian T. Hill, Lisa Rybicki, Theresa A. Urban, Mariana Lucena, Deepa Jagadeesh
Biology of Blood and Marrow Transplantation. 2020-02-01
28 citations
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
Siddharth Kunte, Lisa Rybicki, Auro Viswabandya, Roni Tamari, Asad Bashey
Leukemia. 2021-10-18

Journal Articles

Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation
Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
Lactone synthesis via biotransformations of Gamma-hydroxyamides
Taylor, S.K., Arnold, C.R., Gerds A.T., Ide, N.D., Law K.M., Kling, D.L., Pridgeon M.G., Simons, L.J., Vyvyan, J.R., Yamaoka, J.S., Liao, M.K., Goyne, T.E., Tetrahedron: Asymmetry, 1/1/2004

Abstracts/Posters

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Determinants of "fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. PhysicianÍs Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or ...
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression.
Gerds AT, Dennison B, Latsko J, Houk A, Chisolm S, Huber JM, Stone RM, Maciejewski JP, Komrokji RS, Garcia-Manero G, Steensma DP, Sekeres MA, Blood, American Society of Hematology Annual Meeting, San Francisco, CA, 1/7/2015
Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS).
Cheng C, Siebenaller C, Elson P, Advani AS, Carraway HE, Colaluca K, Hamilton BK, Hobson S, Kalaycio ME, Maciejewski JP, Mukherjee S, Rupp G, Zimmerman C, Sekeres MA, ..., Blood, American Society of Hematology Annual Meeting, San Francisco, CA, 1/6/2015
79 Risk Of Myelodysplastic Syndromes in Well-Differentiated Thyroid Cancers Treated With Radioactive Iodine.
Pleyer C, Sidana S, Erik O, Radivoyevitch T, Advani AS, Gerds AT, Carraway H, Kalaycio M, Maciejewski JP, Sekeres MA, Mukherjee S, Leukemia Research, 1/1/2015
168 Somatic Wiskott-Aldrich Syndrome Protein Family Member 3 (Wasf3) Mutations in Myelodysplastic Syndromes and Related Myeloid Malignancies.
Visconte V, Tabarroki A, Zhang L, Gerds AT, Rogers HJ, Han Y, Barnard J, Shivarov V, Carew J, Tiu RV, Leukemia Research, 1/1/2015
310 Risk of Bone Marrow Failure Conditions in Patients Undergoing Invasive Cardiac Procedures.
Gerds AT, List AF, Giagounidis A, Hellstrom-Lindberg E, Li JS, Swern AS, Sugrue MM, Fenaux P, Sekeres MA, Leukemia Research, 1/1/2015
217 Defining Likelihood of Future Response in Patients With Del(5q) Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.
Gerds AT, List AF, Giagounidis A, Hellstrom-Lindberg E, Li JS, Swern AS, Sugrue MM, Fenaux P, Sekeres MA, Leukemia Research, International Symposium on Myelodysplastic Syndromes, Washington, DC, 1/1/2015
The Impact of Histologic Grade on Acute Graft Versus Host Disease Response and Outcomes.
Narkhede M, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean RM, Duong HK, Gerds A, Hanna R, Hill B, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks R, Majhail NS, Ham..., Biology of Blood and Marrow Transplant, 1/1/2015
Socioeconomic Status Influences Long-Term Outcomes in 1-Year Survivors after Allogeneic Hematopoietic Cell Transplantation.
Fu S, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean RM, Duong HK, Gerds A, Hamilton BK, Hanna R, Hill B, Jagadeesh D, Kalaycio ME, Pohlman B, Sobecks R, Majhail NS, Biology of Blood and Marrow Transplant, 1/1/2015
Bortezomib-Based Induction Therapy PRIOR to High Dose Melphalan and Autologous Hematopoietic CELL Transplantation in Primary Amyloidosis.
Duong HK, Rybicki L, Abounader D, Bolwell B, Kalaycio ME, Valent J, Samaras C, Reu F, Sobecks R, Jagadeesh D, Hamilton B, Andresen S, Gerds A, Hanna R, Pohlman B, Majh..., Biology of Blood and Marrow Transplant, 1/1/2015
Join now to see all

Lectures

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Defining Treatment Strategies for MDS/MPN Overlap Syndromes
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/2/2018
Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal StudyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/1/2018
Graft-Versus-Host-Disease
Cleveland, OH - 1/25/2015
Growth Factors and Their Role in Hematologic Malignancies
Cleveland, OH - 1/24/2015
Integrating Palliative Medicine in Hematologic Malignancies
Cleveland, OH - 1/23/2015
MPN and MDS
Cleveland Clinic Lerner College of Medicine, Cleveland, OH - 1/18/2015
Leukemias
Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 2014, 2015 - 1/16/2015
Acute and Chronic Leukemias
Cleveland, OH - 1/14/2015
MPN's: A Primer
Beachwood, OH - 1/11/2015
Geriatric Anemia is Not Normal: A Practical Guide on the Differential Diagnosis of Underlying Causes
Wheeling, IL - 1/5/2015
Management of challenging PV scenarios: Thrombosis, pregnancy, surgery
Washington, DC - 1/3/2015
A Taste of NOLA brought to CLE, from Ph-like ALL to Targeting CD33
Cleveland, OH - 1/22/2014
Conditioning Regimens for Transplant: A Primer
Cleveland, OH - 1/21/2014
Join now to see all

Other

Cleveland Clinic shares how Twitter is helping save time and connect with patients. Read my perspective article in ASH Clinical News
Aaron Gerds
https://consultqd.clevelandclinic.org/twitter-isnt-just-for-millennials/
New NCCN guidelines for MPNs include use on ruxolitinib but not molecular testing
Consult QD
https://consultqd.clevelandclinic.org/2017/02/diagnostic-treatment-guidelines-established-myeloproliferative-neoplasms
Hematopoietic Cell Transplantation for Myelofibrosis
Gerds, AT, Scott, BL, Deeg, HJ, Myeloproliferative Neoplasms: Clinician's Guide for Apple iOS (Version 8.1), Mesa, Kiladjian, Harris
http://g2npublishing.com/mpn/
1/1/2014

Press Mentions

Dr. Gerds Discusses Patterns of Disease Progression in Low-Risk MyelofibrosisJuly 10th, 2024
AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”February 8th, 2023
Momelotinib Maintains Superiority over Danazol for Myelofibrosis with AnemiaDecember 14th, 2022
Join now to see all